BRAF and non-small cell lung carcinoma: To understand the mutation profiles and distribution of IDH mutations in NSCLC, we compared the eight most common activating driver mutations in NSCLC with (n = 154) and without (n = 17,824) active‐site IDH, including TP53 (60.4% vs. 54.8%), EGFR (e18–e21, 22.7% vs. 37.9%), KRAS (p. G12/13/61, 22.1% vs. 8.2%), BRAF (p. V600E, 6.5% vs. 1.0%), ALK (2.6% vs. 3.2%), PIK3CA (p. E542/E545/H1047, 1.9% vs. 3.4%), ERBB2 (1.9% vs. 1.6%), RET (0.65% vs. 0.7%), and ROS1 (0% vs. 0.6%) (Figure 3).